Invention Grant
- Patent Title: Crimean-Congo hemorrhagic fever virus vaccine
- Patent Title (中): 克里米亚 - 刚果出血热病毒疫苗
-
Application No.: US13829105Application Date: 2013-03-14
-
Publication No.: US09474796B2Publication Date: 2016-10-25
- Inventor: Eric Bergeron , Scott Dusan Pegan , Stuart T. Nichol , Michelle Kay Deaton
- Applicant: Colorado Seminary, which owns and Operates The University of Denver
- Applicant Address: US DC Washington US CO Denver
- Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services,Colorado Seminary, which owns and operates the University of Denver
- Current Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services,Colorado Seminary, which owns and operates the University of Denver
- Current Assignee Address: US DC Washington US CO Denver
- Agency: Kilpatrick Townsend & Stockton LLP
- Agent David Goetz
- Main IPC: C12N7/00
- IPC: C12N7/00 ; A61K39/12 ; A61K39/00
Abstract:
The genetically modified hemorrhagic fever virus of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent.
Public/Granted literature
- US20140050761A1 Crimean-Congo Hemorrhagic Fever Virus Vaccine Public/Granted day:2014-02-20
Information query
